Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
Traitement médicamenteux du diabète de type 2. Recommandation de l'Agence Française de Sécurité Sanitaire des Produits de Santé. Nov. 2006 http://afssaps.sante.fr/pdf/5/rpb/reco- diabete-2006.pdf.
Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, et al. Approved IFCC reference method for measurement of HbA1c in human blood. Clin Chem Lab Med 2002;40:78-89.
Consensus statement on the worldwide standardization of the haemoglobin A1C measurement: the American Diabetes Association, European Association for the Study of Diabetes, International Federation of Clinical Chemistry and Laboratory Medicine, and the International Diabetes Federation. Diabetes Care 2007;30:2399-2400
John WG. Haemoglobin A1c: analysis and standardization. Clin Chem Lab Med 2003;41:1199-1212
Calisti L, Tognetti S. Measure of glycosylated haemoglobin. Acta Biomed 2005;76(Suppl 3):59-62.
Thomas LB, Agosti SJ, Man MA, Mastorides SM. Screening for haemoglobinopathies during routine haemoglobin A1c testing using the Tosoh G7 Glycohaemoglobin analyser. Ann Clin Lab Sci 2007;37:251-255
Joutovsky A, Hadzi-Nesic J, Nardi MA. HPLC retention time as a diagnostic tool for haemoglobin variants and haemoglobinopathies: a study of 60000 samples in a clinical diagnostic laboratory. Clin Chem 2004;50:1736-1747
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053
NCCLS (USA) National Committee for Clinical Laboratory Standards, Evaluation Protocols, 1994. ISBN 1-56238-217-9
Gibb I, Parnham A, Fonfrède M, Lecock F. Multicentre evaluation of Tosoh glycohaemoglobin analyser. Clin Chem 1999; 45:1833-1841
Gremmels H-D, Richter A, Watzke I. Evaluation of the haemoglobin A1c-analyser Tosoh HLC-723 G7. Clin Lab 2003;49: 243-250
Ou Ching-Nan, Rognerud CL. Rapid analysis of haemoglobin variants by cation-exchange HPLC. Clin Chem 1993;39:820-824
Chevenne D, Fonfrède M, Ducrocq R, Chauffert M, Trivin F. Uremia and HbA1c measurement by HPLC. Diabetes Care 1998;21:463-464
Monnier L, Benichou M, Charra-Ebrard S, Boegner C, Colette C. An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. Diab Metab 2005;31:101-109
McCarter R, Hempe J, Gomez R, Chalew S. Biological variation in HbA1c predicts risk of retinopathy in type 1 diabetes. Diabetes Care 2004;27:1259-1264
McCarter R, Hempe M, Chalew S. Mean blood glucose and biological variation have greater influence on HbA1c levels than glucose instability. Diabetes Care 2006;29:352-355
Tseng C-L, Brimacombe M, Xie M, Rajan M, Wang H, Kolassa J, et al. Seasonal patterns in monthly haemoglobin A1c values. Am J Epidemiol 2005;161:565-574
Dasgupta K, Chan C, Da Costa D, Pilote L, De Civita M, Ross N, et al. Walking behaviour and glycemic control in type 2 diabetes: seasonal and gender differences-study design and methods. Cardiovasc Diabetol 2007;6:1.
ADVANCE Collaborative Group. Intensive blood glucose con trol and vascular outcomes in patients with Type 2 diabetes. N Engl J Med 2008;358:2560-2572
Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008;358:2545-2559
Rohlfing C, Wiedmeyer H-M, Little R, Grotz VL, Tennill A, England J, et al. Biological variation of glycohaemoglobin. Clin Chem 2002;48:1116-1118
Ahuja S, Dong M, editors. Handbook of pharmaceutical analysis by HPLC: separation science and technology. Academic Press, 2005.
Weykamp CW, Penders TJ, Siebelder CW, Muskiet FA, van der Slik W. Interference of carbamylated and acetylated haemoglobins in assays of glycohaemoglobin by HPLC, electrophoresis, affinity chromatography, and enzyme immunoassay. Clin Chem 1993;39:138-142
Meijs MF, Dijkhorst-Oei LT, van Loo R, Bosma RJ, Weycamp CW, Wielders JP. Does carbamylated hemoglobin still affect the analysis of HbA1c in uremic and hyperglycaemic patients? Clin Chem Lab Med 2008;46:1791-1792
Little RR, Rohlfing CL, Hanson S, Connolly S, Higgins T, Weycamp CW, et al. Effect of haemoglobin (Hb) E and HbD traits on measurement of glycated Hb (HbA1c) by 23 methods. Clin Chem 2008;54:1277-1282
Roberts WL, Safar-Pour S, De BK, Rohlfing CL, Weykamp CW, Little RR. Effects of haemoglobin C and S traits on glycohaemoglobin measurements by eleven methods. Clin Chem 2005;4:776-778
Samaan S, Lesellin A, Baron S, Fonfrède M. Evaluation de l'analyseur G8 et du logiciel PIANO (Tosoh Bioscience) pour la determination de l'hémoglobine A1c. Spectra Biologie 2007; 161:38-45.